Pulmonary Arterial Hypertension News and Research RSS Feed - Pulmonary Arterial Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

United Therapeutics Corporation today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. [More]

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension. [More]
Japanese PAH patient prognosis ‘good’

Japanese PAH patient prognosis ‘good’

Japanese patients respond well to pulmonary arterial hypertension-targeted drugs and may have a good prognosis with long-term survival, study findings suggest. [More]
ECG abnormalities progress during pulmonary arterial hypertension course

ECG abnormalities progress during pulmonary arterial hypertension course

Researchers have identified a number of electrocardiography variables that progress between diagnosis and death in patients with pulmonary arterial hypertension. [More]

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology. [More]
Special publication details breakthrough research on causes of vascular disease

Special publication details breakthrough research on causes of vascular disease

The world's leading voices in the fight against Pulmonary Hypertension have compiled a special publication detailing the breakthrough research into the causes of this debilitating vascular disease. [More]
Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, announced today that its investor group and employee shareholders have reached a definitive agreement to sell the Commercial Business to Madison Dearborn Partners in a transaction valued at approximately $1.6 billion. [More]

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity. [More]

6MWT wording change could enhance serial utility

Researchers have found that the distance patients cover during the 6-minute walk test depends on the instructions they are given, indicating that changing the current protocol may enhance the accuracy and reproducibility of the test. [More]
ATS and ACCP release five recommendations for tests, procedures in pulmonary medicine

ATS and ACCP release five recommendations for tests, procedures in pulmonary medicine

A list released today identified five commonly performed tests and procedures in pulmonary medicine that may not always be necessary. The list, part of the ABIM Foundation's Choosing Wisely® campaign, was produced by a collaborative task force assembled by the American Thoracic Society (ATS) and the American College of Chest Physicians (ACCP). [More]

New pulmonary medicine list includes five recommendations to improve patient care and outcomes

A list released today identified five commonly performed tests and procedures in pulmonary medicine that may not always be necessary. The list, part of the ABIM Foundation’s Choosing Wisely campaign, was produced by a collaborative task force assembled by the American Thoracic Society and the American College of Chest Physicians. [More]

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

​The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation. [More]

Adempas drug gets FDA approval for treatment of pulmonary hypertension

The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally high blood pressure in the arteries of the lungs. [More]

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening. [More]
New classification criteria for systemic sclerosis published in ACR journal

New classification criteria for systemic sclerosis published in ACR journal

New classification criteria for systemic sclerosis have just been published and are more sensitive than the 1980 criteria, enabling earlier identification and treatment of this disabling autoimmune disease. [More]

PGI2 analogs, PDE5 inhibitors stimulate enhanced release of vasodilator ATP from human RBCs

Researchers at Saint Louis University School of Medicine have discovered a novel interaction between prostacyclin analogs and phosphodiesterase 5 inhibitors, two groups of drugs used in the treatment of pulmonary arterial hypertension. [More]

Inhalable gene therapy may restore function of crucial enzyme to reverse deadly PAH

The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai. [More]
Scientists identify new genetic mutations that can cause pulmonary arterial hypertension

Scientists identify new genetic mutations that can cause pulmonary arterial hypertension

Columbia University Medical Center (CUMC) scientists have identified new genetic mutations that can cause pulmonary arterial hypertension (PAH), a rare fatal disease characterized by high blood pressure in the lungs. [More]

Progress made in understanding Pulmonary Arterial Hypertension

The next step has been made into isolating the origin of cells linked to the progressive disorder Pulmonary Arterial Hypertension. [More]
Nutritional supplement may improve survival rates of babies born with heart defects

Nutritional supplement may improve survival rates of babies born with heart defects

A common nutritional supplement may be part of the magic in improving the survival rates of babies born with heart defects, researchers report. Carnitine, a compound that helps transport fat inside the cell powerhouse where it can be used for energy production, is currently used for purposes ranging from weight loss to chest pain. [More]